

## 64. Counseling to Prevent Gynecologic Cancers

### RECOMMENDATION

There is insufficient evidence to recommend for or against routine counseling of women about measures for the primary prevention of gynecologic cancers. Clinicians counseling women about contraceptive practices should include information on the potential benefits of oral contraceptives, barrier contraceptives, and tubal sterilization with respect to specific gynecologic cancers (see Chapter 63). Clinicians should also promote other practices (maintaining desirable body weight, smoking cessation, and safe sex practices) that may reduce the incidence of certain gynecologic cancers and have other proven health benefits (see Chapters 21, 54, and 62).

### Burden of Suffering

Gynecologic malignancies are an important cause of morbidity and mortality in women.<sup>1</sup> Ovarian cancer is the fourth most common cause of death from cancer among women of all ages in the U.S.<sup>2</sup> Estimates for 1995 anticipated that there would be 15,800 new cases and 4,800 deaths from cervical cancer, 32,500 new cases and 5,900 deaths from endometrial cancer, and 26,600 new cases and 14,500 deaths from ovarian cancer.<sup>2</sup> Although Papanicolaou (Pap) smear screening has helped reduce mortality from cervical cancer (see Chapter 9), there are no screening strategies that have been proved effective in reducing mortality from endometrial or ovarian cancer (see Chapter 14).

Even when cancers are detected early, the treatment of invasive cervical cancer, endometrial cancer, and ovarian cancer involves surgery and often additional radiation therapy or chemotherapy. Despite aggressive treatment, 5-year survival of women with ovarian cancer is only about 40%.<sup>2</sup> In addition to the costs and morbidity from treatment, the loss of reproductive function and ovarian function can have important psychological and physical consequences in premenopausal women. Compared to early detection and treatment, primary preventive strategies offer the potential to reduce both mortality and morbidity from gynecologic cancers.<sup>3</sup>

### Efficacy of Risk Reduction

*Cervical Cancer.* Certain sexual behaviors are consistently associated with an increased risk for cervical cancer. Women who became sexually active at an early age and women with a high lifetime number of sex partners have a significantly increased risk of cervical cancer.<sup>4</sup> Use of barrier contraception (diaphragm and condoms) and spermicides (foam or contraceptive jelly) is associated with lower risk of invasive cervical cancer. Of 11 case-control studies<sup>5–15</sup> and one cohort study<sup>16</sup> examining this issue, 10 reported that at least one of these methods of contraception was associated with a significantly lower risk of cervical cancer. This protective effect persisted after controlling for the potential influence of age at first intercourse, cytology screening history, and smoking.<sup>11,13,16</sup> Substantial reductions in risk of invasive cervical cancer were observed among both condom users (odds ratios [OR] = 0.4–0.8, i.e., 20–60% reduction in risk)<sup>11</sup> and diaphragm users (OR = 0.2–0.7).<sup>5,16</sup> A longer duration of use was associated with greater protection.<sup>11</sup> In one study, barrier contraceptives reduced risk only among women with multiple sex partners.<sup>13</sup> Spermicides afforded protection comparable to physical barriers in three studies;<sup>12–14</sup> proving an independent effect of spermicides is difficult since they are often used in conjunction with other barrier methods.

The apparent protective effect of avoiding high-risk sexual activity and using barrier contraceptives or spermicides is presumably mediated through reducing the incidence of sexually transmitted diseases (STDs). Human papillomavirus (HPV) appears to be an important factor in the etiology of cervical cancers:<sup>1,4,17</sup> women with HPV infection have a 10-fold higher risk of developing invasive cervical cancer.<sup>18</sup> Direct evidence that spermicides or barrier contraception prevents HPV infection is limited, however.<sup>19</sup> Despite *in vitro* activity against many sexually transmitted viruses and bacteria, nonoxynol-9 did not inhibit papillomaviruses in one recent study.<sup>20</sup>

Smoking is also associated with an increased risk of invasive cervical cancer.<sup>17,21–23</sup> Recent case-control studies report a 2-fold increased risk among smokers versus nonsmokers; risk remained significantly elevated after controlling for other risk factors.<sup>13,24–26</sup> Most studies suggest a dose-response relationship between risk and cigarette use. Ex-smokers have a risk below that of current smokers, but higher than in nonsmokers.<sup>13,25–27</sup>

Some dietary factors, such as high levels of vitamin C, have also been associated with reduced risk of cervical cancer.<sup>28,29</sup> Two case-control studies have reported significantly lower risk (30–50% lower) in women with the highest versus lowest vitamin C intake.<sup>30,31</sup> The relationship of dietary folate, vitamin E, and dietary carotenoids to invasive cervical cancer is unclear.<sup>4,29,32</sup> Attributing a protective effect to any specific dietary compo-

ment is problematic, however, due to the possible influence of other dietary constituents or lifestyle factors.<sup>29,33</sup> The mechanisms by which dietary factors might protect against cervical neoplasia remain speculative, but include antioxidant effects or enhancement of the immune system.<sup>30</sup>

Long-term use (>5 years) of oral contraceptives (OCs) has been associated with an increased risk of invasive cervical cancer,<sup>17,34,35</sup> which remains elevated after controlling for sexual history and cytologic screening.<sup>36–38</sup> Two large collaborative case-control studies<sup>36,38</sup> and a large cohort study in the United Kingdom<sup>39</sup> each reported increased risks of cervical cancer among women who have ever used OCs (OR = 1.2–1.8). A meta-analysis of 18 methodologically sound epidemiologic studies<sup>40</sup> reported an increased risk for invasive cancer among OC users (OR = 1.21, 95% confidence interval [CI], 1.1 to 1.4), with increasing risk with longer durations of use. Although a causal association between OC use and cervical cancer is biologically plausible (OCs cause endocervical hyperplasia), it is difficult to exclude the effect of other risk factors among long-term OC users (e.g., multiple sex partners or low use of barrier contraceptives).<sup>17,41</sup>

*Endometrial Cancer.* Childbearing seems to protect against endometrial cancer,<sup>42</sup> and the use of combination oral contraceptives is consistently associated with a lower risk of endometrial cancer. Of 13 case-control studies,<sup>38,43–54</sup> and three cohort studies,<sup>39,55,56</sup> all but two indicated a protective effect of oral contraceptive use (OR = 0.1–0.6).<sup>1</sup> In the largest study, the Cancer and Steroid Hormone (CASH) study which involved 433 cases and 3191 controls, women who had used combination OCs for at least 1 year had an age-adjusted OR of endometrial cancer of 0.6 (95% CI, 0.3 to 0.9).<sup>51</sup> The protective effect began after 1 year of use and lasted up to 15 years after discontinuing the pills, but it was most evident in nulliparous women. Two of three cohort studies have reported similar protective effects.<sup>39,51,56</sup> The Royal College of General Practitioners study from the United Kingdom followed 47,000 women and found an 80% reduction in risk (RR = 0.2; 95% CI, 0.0 to 0.7) among OC users.<sup>39</sup>

In the CASH study, lower risk was seen with a variety of different combination OCs (OR = 0.2–0.7).<sup>51</sup> In one report, high-dose estrogen/low-dose progestin pills were less effective (OR = 1.1; 95% CI, 0.1 to 10.0) than low-dose estrogen/high-dose progestin pills (OR = 0.0; 95% CI, 0.0 to 1.1),<sup>57</sup> but the importance of formulation remains controversial.<sup>58</sup> Other unresolved questions include the duration of protection, since most endometrial cancer occurs after age 60, and the effects of past OC use in women taking postmenopausal hormone therapy.<sup>58</sup> Use of unopposed estrogen after the menopause is associated with an increased risk of endometrial cancer, but the risk is reduced or eliminated by regimens combining estrogen with progestins (see Chapter 68).<sup>59</sup>

Overweight women have an increased risk of endometrial cancer.<sup>17</sup> Nineteen reports, using varying definitions of overweight, observed relative risks ranging from 1.0–20.3 for overweight women.<sup>42,54,60</sup> Most RRs were above 2, and body mass was significantly correlated with cancer risk. In contrast with several other diseases, the total amount of adiposity may be more important than its distribution (i.e., waist-hip ratio) in the development of endometrial cancer.<sup>61</sup>

The protective effects of OCs and of normal weight may reflect the adverse effects on the endometrium of unopposed estrogen stimulation.<sup>62</sup> Obesity is associated with increased anovulation, increasing levels of circulating estrogens, and lower progesterone levels, due to conversion of androstenedione into estrone (an estrogen) by adipose tissue.<sup>17</sup> OCs containing progestins reduce the period of unopposed estrogen stimulation of the endometrium.

*Ovarian Cancer.* Childbearing reduces the risk of ovarian cancer,<sup>63</sup> and use of oral contraceptives may have a similar effect. Of 20 case-control studies<sup>38,49,64–81</sup> of the association between OC use and ovarian cancer, all but two found a lower risk among users of OCs.<sup>79,80</sup> Three cohort studies, one from the U.S.<sup>55</sup> and two from the U.K.,<sup>39,82</sup> all reported substantial protective effects of oral contraceptives (RR = 0.4, 0.6, and 0.3, respectively). In a 1992 meta-analysis of these studies, the pooled risk of ovarian cancer was 30–40% lower in OC users in case-control studies, and 60% lower in cohort studies (RR = 0.4; 95% CI, 0.3 to 0.8).<sup>83</sup> In the CASH study, with 546 cases and 4,228 controls,<sup>64</sup> a protective effect was evident after as little as 3–6 months of pill use, persisted for at least 15 years after discontinuation, increased with duration of use (80% reduction after 10 or more years), and was evident for each of 11 commonly used formulations.

Breastfeeding also appears to lower a woman's risk of ovarian cancer.<sup>44,64,69,79,84–86</sup> In an analysis of 12 case-control studies, women who had breast fed an infant had a 20% lower risk of ovarian cancer (OR = 0.8; 95% CI, 0.7 to 1.0) than parous women who had never breastfed,<sup>63</sup> each month of breastfeeding was associated with a 1% reduction in overall risk. Childbearing, OC use, and breastfeeding may reduce the risk of malignant transformation by prolonging periods of anovulation or suppressing gonadotropin levels.

Tubal sterilization is associated with a lower risk of ovarian cancer in a number of case-control studies (OR = 0.2–0.9).<sup>63,78,80,86–89</sup> A recent, large cohort study of nearly 78,000 premenopausal nurses demonstrated a substantial reduction in subsequent ovarian cancer among women who had tubal ligation (RR = 0.3; 95% CI, 0.2 to 0.6).<sup>90</sup> A meta-analysis of published studies estimated that tubal sterilization reduced risk by 40% (RR = 0.6; 95% CI, 0.4 to 0.9).<sup>90</sup> This protective effect may be due to isolation of the

ovaries from carcinogens imported from the external environment.<sup>91,92</sup> Hysterectomy, which has a similar effect, is associated with a somewhat smaller reduction in ovarian cancer (RR = 0.6–0.7).<sup>63,88,90</sup>

Recent trends in the U.S. and U.K. are consistent with a protective effect of OCs on endometrial and ovarian cancer.<sup>62,93,94</sup> In women under 50 (those with greatest exposure to combination OCs) incidence of endometrial cancer fell 28% between 1973 and 1986 in the U.S., and incidence of ovarian cancer declined 20%, similar to changes predicted based on a protective effect of OCs.<sup>62,95</sup> Interpreting temporal trends is complicated by changes in other risk factors (e.g., parity, estrogen use) and in screening practices, however.

### Effectiveness of Counseling

There are no data to determine whether counseling women specifically about primary prevention of gynecologic cancers influences their choice of contraception or their attention to other risk factors (sexual practices, weight control, diet, or smoking). Women and men choosing a particular method of contraception may regard other considerations—costs, effectiveness, convenience, and protection against STDs—as more important than long-term effects on gynecologic cancers, which account for less than 10% of all cancer deaths in women. Some women may place a higher value on reducing their risk of cancer, however, or have risk factors that place them at higher risk for specific cancers. These important noncontraceptive benefits of modern OCs are often not mentioned when the risks and benefits of these agents are discussed. A recent survey of female employees, students, and faculty at a large university revealed that 80% did not know that use of OCs protects against ovarian cancer.<sup>96</sup>

There is only limited evidence that clinical counseling can reduce the high-risk sexual behaviors in young women that put them at future risk for cervical cancer (see Chapter 62). Early sexual activity and multiple sex partners remain common among young men and women. Counseling men is more effective than counseling women in increasing regular use of condoms.<sup>97</sup> Although methods under female control (diaphragms, spermicides and female condom) may also be protective, they remain less popular, especially among high-risk populations.<sup>98</sup>

### Discussion

A large body of evidence suggests that specific measures can reduce the risk of cervical, ovarian, or endometrial cancer. Although this evidence comes from epidemiologic studies rather than from controlled trials, various considerations support the conclusion that certain interventions have a protective effect against cancer:<sup>99</sup> the observed associations are strong,

consistent in multiple studies, biologically plausible, dose-dependent, and not explained by differences in other risk factors. Evidence of a protective effect of OCs on endometrial and ovarian cancer is compelling and stronger than that for adverse effects of OCs on cervical cancer. Furthermore, ovarian and endometrial cancers together account for four times as many deaths as cervical cancer, which can often be prevented by effective screening. Tubal sterilization, hysterectomy, and breastfeeding also appear to reduce risk of ovarian cancer, but evidence is more limited. Other measures (breast-feeding, avoiding smoking, obesity, and high-risk sexual activity) also appear to reduce the risk of specific gynecologic cancers, and there are other compelling reasons to promote these measures routinely for all patients. In contrast, the evidence is not yet sufficient to recommend specific diets to reduce the risk of cervical cancer. More information may come from ongoing chemoprevention trials of vitamin supplementation.<sup>100</sup>

Women selecting contraception need to consider not only the convenience and effectiveness of a given method, but other important noncontraceptive risks and benefits as well (see Chapter 63).<sup>101,102</sup> The favorable effects of OCs on endometrial and ovarian cancer are more consistent yet less widely appreciated than some of the possible risks of OCs, such as cardiovascular disease or breast cancer. Despite the relative safety of oral contraceptives, however, it is not clear that the potential benefits with respect to ovarian and endometrial cancer would justify the expense, inconvenience, and possible risks of OC use in women who do not otherwise need contraception. One study estimated that treating 100,000 women with OCs for 8 years might prevent 193 cases of ovarian cancer and 197 cases of endometrial cancer;<sup>103</sup> net benefit, however, would be negligible if OCs increase the risk of cervical or breast cancer. Nonetheless, for women with specific concerns about gynecologic cancers, information about effective measures that they can take to reduce their risk of cervical, ovarian, or endometrial cancer may be particularly useful.

#### CLINICAL INTERVENTION

There is insufficient evidence to recommend for or against routine counseling of female patients about measures to reduce the risk of cervical, ovarian, and endometrial cancer (“C” recommendation). Clinicians counseling women about contraceptive practices should include information about the potential benefits of specific methods with respect to gynecologic cancers (see Chapter 63). These potential benefits include reduced risks of ovarian and endometrial cancer in women using OCs, cervical cancer in women who use barrier contraception and spermicides, and ovarian cancer after tubal sterilization. All women should be counseled about effective means to prevent STDs (see Chapter 62) and about the benefits of

breastfeeding (see Chapter 56), avoiding obesity (see Chapter 21), and avoiding tobacco use (see Chapter 54).

Note: See background paper: Grimes DA, Economy KE. Primary prevention of gynecologic malignancies. *Am J Obstet Gynecol* 1995;172:227–235.

The draft of this chapter was prepared for the U.S. Preventive Services Task Force by David Grimes, MD, and David Atkins, MD, MPH, based on a background paper by David Grimes, MD, and Katherine E. Economy, MD.

## REFERENCES

1. Grimes DA, Economy KE. Primary prevention of gynecologic malignancies. *Am J Obstet Gynecol* 1995;172: 227–235.
2. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. *CA Cancer J Clin* 1995;45:8–30.
3. Last JM, ed. Scope and methods of prevention. In: Maxcy-Rosenau public health and preventive medicine. 11th ed. New York: Appleton-Century-Crofts, 1980:3–8.
4. Brinton LA. Epidemiology of cervical cancer—overview. In: Munoz N, Bosch FX, Shah KV, Meheus A, eds. *The epidemiology of cervical cancer and human papillomavirus*. Lyon, France: IARC, 1992:3–23.
5. Parazzini F, Negri E, La Vecchia C, Fedele L. Barrier methods of contraception and the risk of cervical neoplasia. *Contraception* 1989;40:519–530.
6. Boyd JT, Doll R. A study of the aetiology of carcinoma of the cervix uteri. *Br J Cancer* 1964;18:419–434.
7. Aitken-Swan J, Baird D. Cancer of the uterine cervix in Aberdeenshire. Etiological aspects. *Br J Cancer* 1966;20: 642–659.
8. Martin CE. Epidemiology of cancer of the cervix. II. Marital and coital factors in cervical cancer. *Am J Public Health* 1967;57:803–814.
9. Boyce JG, Lu T, Nelson JH, Fruchter RG. Oral contraceptives and cervical carcinoma. *Am J Obstet Gynecol* 1977;128:761–766.
10. Fasal E, Simmons ME, Kampert JB. Factors associated with high and low risk of cervical neoplasia. *J Natl Cancer Inst* 1981;66:631–636.
11. Peters RK, Thomas D, Hagan DG, et al. Risk factors for invasive cervical cancer among Latinas and non-Latinas in Los Angeles County. *J Natl Cancer Inst* 1986;77:1063–1077.
12. Celentano DD, Klassen AC, Weisman CS, Rosenshein NB. The role of contraceptive use in cervical cancer: the Maryland cervical cancer case-control study. *Am J Epidemiol* 1987;126:592–604.
13. Slattery ML, Overall JC Jr, Abbott TM, et al. Sexual activity, contraception, genital infections, and cervical cancer: support for a sexually transmitted disease hypothesis. *Am J Epidemiol* 1989;130:248–258.
14. Hildesheim A, Brinton LA, Malin K, et al. Barrier and spermicidal contraceptive methods and risk of invasive cervical cancer. *Epidemiology* 1990;1:266–272.
15. Brinton LA, Reeves WC, Brenes MM, et al. Oral contraceptive use and risk of invasive cervical cancer. *Int J Epidemiol* 1990;19:4–11.
16. Wright NH, Vessey MP, Kenward B, et al. Neoplasia and dysplasia of the cervix uteri and contraception: a possible protective effect of the diaphragm. *Br J Cancer* 1978;38:273–279.
17. Daly MB, Bookman MA, Lerman CE. Female reproductive tract: cervix, endometrium, ovary. In: Greenwald P, Kramer BS, Weed DL, eds. *Cancer prevention and control*. New York: Marcel Dekker, 1995.
18. Schiffman MH. Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. *J Natl Cancer Inst* 1992;84:394–398.
19. Cates W, Stone KM. Family planning, sexually transmitted diseases and contraceptive choice: a literature update—Part I. *Fam Plann Perspect* 1992;24:75–84.
20. Hermonat PL, Daniel RW, Shah KV. The spermicide nonoxonyl-9 does not inactivate papillomavirus. *Sex Transm Dis* 1992;19:203–205.
21. Winkelstein W Jr. Smoking and cervical cancer—current status: a review. *Am J Epidemiol* 1990;131:945–957.
22. Baron JA, Byers T, Greenberg ER, et al. Cigarette smoking in women with cancers of the breast and reproductive organs. *J Natl Cancer Inst* 1986;77:677–680.



23. Slattery ML, Robison LM, Schuman KL, et al. Cigarette smoking and exposure to passive smoking are risk factors for cervical cancer. *JAMA* 1989;261:1594–1598.
24. La Vecchia C, Franceschi S, Decarli A, et al. Cigarette smoking and the risk of cervical neoplasia. *Am J Epidemiol* 1986;123:22–29.
25. Brisson J, Roy M, Fortier M, et al. Condyloma and intraepithelial neoplasia of the uterine cervix: a case-control study. *Am J Epidemiol* 1988;128:337–342.
26. Brinton LA, Schairer C, Haenszel W, et al. Cigarette smoking and invasive cervical cancer. *JAMA* 1986;255: 3265–3269.
27. Mayberry RM. Cigarette smoking, herpes simplex virus type 2 infection, and cervical abnormalities. *Am J Public Health* 1985;75:676–678.
28. Block G, Patterson B, Subar A. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. *Nutr Cancer* 1992;18:1–29.
29. Pottischman N. Nutritional epidemiology of cervical neoplasia. *J Nutr* 1993;123:424–429.
30. Herrero R, Pottischman N, Brinton LA, et al. A case-control study of nutrient status and invasive cervical cancer. I. Dietary indicators. *Am J Epidemiol* 1991;134:1335–1346.
31. Verreault R, Chu J, Mandelson M, Shy K. A case-control study of diet and invasive cervical cancer. *Int J Cancer* 1989;43:1050–1054.
32. Schneider A, Shah K. The role of vitamins in the etiology of cervical neoplasia: an epidemiological review. *Arch Gynecol Obstet* 1989;246:1–13.
33. Brock KE, Berry G, Mock PA, et al. Nutrients in diet and plasma and risk of in situ cervical cancer. *J Natl Cancer Inst* 1988;80:580–585.
34. Hannaford PC. Cervical cancer and methods of contraception. *Adv Contracept* 1991;7:317–324.
35. Brinton LA. Oral contraceptives and cervical neoplasia. *Contraception* 1991;43:581–595.
36. Brinton LA, Huggins GR, Lehman HF, et al. Long-term use of oral contraceptives and risk of invasive cervical cancer. *Int J Cancer* 1986;38:339–344.
37. Parazzini F, La Vecchia C, Negri E, Maggi R. Oral contraceptive use and invasive cervical cancer. *Int J Epidemiol* 1990;19:259–263.
38. Thomas DB. The WHO collaborative study of neoplasia and steroid contraceptives: the influence of combined oral contraceptives on risk of neoplasms in developing and developed countries. *Contraception* 1991;43:695–710.
39. Beral V, Hannaford P, Kay C. Oral contraceptive use and malignancies of the genital tract. Results from the Royal College of General Practitioners' oral contraception study. *Lancet* 1988;ii:1331–1335.
40. Delgado-Rodriguez M, Sillero-Arenas M, Martin-Moreno JM, et al. Oral contraceptives and cancer of the cervix uteri. A meta-analysis. *Acta Obstet Gynecol Scand* 1992;71:368–376.
41. WHO Scientific Group. Oral contraceptives and neoplasia. WHO Technical Report series, no. 817. Geneva: World Health Organization, 1992.
42. Parazzini F, La Vecchia C, Bocciolone L, Franceschi S. The epidemiology of endometrial cancer. *Gynecol Oncol* 1991;41:1–16.
43. Horwitz RI, Feinstein AR. Case-control study of oral contraceptive pills and endometrial cancer. *Ann Intern Med* 1979;91:226–227.
44. Weiss NS, Sayvetz TA. Incidence of endometrial cancer in relation to the use of oral contraceptives. *N Engl J Med* 1980;302:551–554.
45. Kaufman DW, Shapiro S, Slone D, et al. Decreased risk of endometrial cancer among oral contraceptive users. *N Engl J Med* 1980;303:1045–1047.
46. Kelsey JL, LiVolsi VA, Holford TR, et al. A case-control study of cancer of the endometrium. *Am J Epidemiol* 1982;116:333–342.
47. Hulka BS, Chambless LE, Kaufman DG, et al. Protection against endometrial carcinoma by combination-product oral contraceptives. *JAMA* 1982;247:475–477.
48. Henderson BE, Casagrande JT, Pike MC, et al. The epidemiology of endometrial cancer in young women. *Br J Cancer* 1983;47:749–756.
49. La Vecchia C, Decarli A, Fasoli M, et al. Oral contraceptives and cancers of the breast and of the female genital tract. Interim results from a case-control study. *Br J Cancer* 1986;54:311–317.
50. Pettersson B, Adami HO, Bergstrom R, Johansson EDB. Menstruation span - a time-limited risk factor for endometrial carcinoma. *Acta Obstet Gynecol Scand* 1986;65:247–255.
51. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. Combination oral contraceptive use and the risk of endometrial cancer. *JAMA* 1987;257: 796–800.



52. Koumantaki Y, Tzonou A, Koumantakis E, et al. A case-control study of cancer of the endometrium in Athens. *Int J Cancer* 1989;43:795-799.
53. Brinton LA, Hoover RN, and the Endometrial Cancer Collaborative Group. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. *Obstet Gynecol* 1993;81:265-271.
54. Jick SS, Walker AM, Jick H. Oral contraceptives and endometrial cancer. *Obstet Gynecol* 1993;82:931-935.
55. Ramcharan S, Pellegrin FA, Ray R, Hsu J-P. The Walnut Creek contraceptive drug study: a prospective study of the side effects of oral contraceptives, vol 3. Bethesda: National Institute of Child Health and Human Development, 1981.
56. Trapido EJ. A prospective cohort study of oral contraceptives and cancer of the endometrium. *Int J Epidemiol* 1983;12:297-300.
57. Rosenblatt KA, Thomas DB, and the WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinoma. *Int J Cancer* 1991;49:870-874.
58. Schlesselman JJ. Oral contraceptives and neoplasia of the uterine corpus. *Contraception* 1991;43:557-579.
59. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. *Ann Intern Med* 1992;117:1016-1037.
60. Sturgeon SR, Brinton LA, Berman ML, et al. Past and present physical activity and endometrial cancer risk. *Br J Cancer* 1993;68:584-589.
61. Folsom AR, Kaye SA, Potter JD, Prineas RJ. Association of incident carcinoma of the endometrium with body weight and fat distribution in older women: early findings of the Iowa Women's Health Study. *Cancer Res* 1989;49: 6828-6831.
62. Henderson BE, Ross RK, Pike MC. Hormonal chemoprevention of cancer in women. *Science* 1993; 259:633-638.
63. Whittemore AS, Harris R, Itnyre J, and the Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 U.S. case-control studies. II. Invasive epithelial ovarian cancers in white women. *Am J Epidemiol* 1992;136:1184-1203.
64. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. The reduction in risk of ovarian cancer associated with oral-contraceptive use. *N Engl J Med* 1987;316:650-655.
65. Newhouse ML, Pearson RM, Fullerton JM, et al. A case-control study of carcinoma of the ovary. *Br J Prev Soc Med* 1977;31:148-153.
66. Casagrande JT, Louie EW, Pike MC, et al. "Incessant ovulation" and ovarian cancer. *Lancet* 1979; 2:170-173.
67. Annegers JF, Strom H, Decker DG, et al. Ovarian cancer: incidence and case-control study. *Cancer* 1979;43:723-729.
68. McGowan L, Parent L, Lednar W, Norris HJ. The woman at risk for developing ovarian cancer. *Gynecol Oncol* 1979;7:325-344.
69. Hildreth NG, Kelsey JL, LiVolsi VA, et al. An epidemiologic study of epithelial carcinoma of the ovary. *Am J Epidemiol* 1981;114:398-405.
70. Willett WC, Bain C, Hennekens CH, et al. Oral contraceptives and risk of ovarian cancer. *Cancer* 1981;48:1684-1687.
71. Weiss NS, Lyon JL, Liff JM, et al. Incidence of ovarian cancer in relation to the use of oral contraceptives. *Int J Cancer* 1981;28:669-671.
72. Rosenberg L, Shapiro S, Slone D, et al. Epithelial ovarian cancer and combination oral contraceptives. *JAMA* 1982;247:3210-3212.
73. Franceschi S, La Vecchia C, Helmrich SP, et al. Risk factors for epithelial ovarian cancer in Italy. *Am J Epidemiol* 1982;115:714-719.
74. Cramer DW, Hutchison GB, Welch WR, et al. Factors affecting the association of oral contraceptives and ovarian cancer. *N Engl J Med* 1982;307:1047-1051.
75. Tzonou A, Day NE, Trichopoulos D, et al. The epidemiology of ovarian cancer in Greece: a case-control study. *Eur J Cancer Clin Oncol* 1984;20:1045-1052.
76. Wu ML, Whittemore AS, Paffenbarger RS, et al. Personal and environmental characteristics related to epithelial ovarian cancer. I. Reproductive and menstrual events and oral contraceptive use. *Am J Epidemiol* 1988;128: 1216-1227.

77. Harlow BL, Weiss NS, Roth GJ, et al. Case-control study of borderline ovarian tumors: reproductive history and exposure to exogenous female hormones. *Cancer Res* 1988;48:5849–5852.
78. Booth M, Beral V, Smith P. Risk factors for ovarian cancer: a case-control study. *Br J Cancer* 1989;60:592–598.
79. Hartge P, Schiffman MH, Hoover R, et al. A case-control study of epithelial ovarian cancer. *Am J Obstet Gynecol* 1989;161:10–16.
80. Shu XO, Brinton LA, Gao YT, Yuan JM. Population-based case-control study of ovarian cancer in Shanghai. *Cancer Res* 1989;49:3670–3674.
81. Parazzini F, La Vecchia C, Negri E, et al. Oral contraceptive use and the risk of ovarian cancer: an Italian case-control study. *Eur J Cancer* 1991;27:594–598.
82. Vessey M, Metcalfe A, Wells C, et al. Ovarian neoplasms, functional ovarian cysts, and oral contraceptives. *BMJ* 1987;294:1518–1520.
83. Hankinson SE, Colditz GA, Hunter DJ, et al. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. *Obstet Gynecol* 1992;80:708–714.
84. Cramer DW, Hutchison GB, Welch WR, et al. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. *J Natl Cancer Inst* 1983;71:711–716.
85. Nasca PC, Greenwald P, Chorost S, et al. An epidemiologic case-control study of ovarian cancer and reproductive factors. *Am J Epidemiol* 1984;119:705–713.
86. Whittemore AS, Wu ML, Paffenbarger RS Jr, et al. Personal and environmental characteristics related to epithelial ovarian cancer. II. Exposures to talcum powder, tobacco, alcohol, and coffee. *Am J Epidemiol* 1988;128:1228–1240.
87. Mori M, Harabuchi I, Miyake H, et al. Reproductive, genetic, and dietary factors for ovarian cancer. *Am J Epidemiol* 1988;128:771–777.
88. Irwin KL, Weiss NS, Lee NC, Peterson HB. Tubal sterilization, hysterectomy, and the subsequent occurrence of epithelial ovarian cancer. *Am J Epidemiol* 1991;134:362–369.
89. Koch M, Jenkins H, Gaedke H. Risk factors of ovarian cancer of epithelial origin: a case control study. *Cancer Detect Prev* 1988;13:131–136.
90. Hankinson SE, Hunter DJ, Colditz GA, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer: a prospective study. *JAMA* 1993;270:2813–2818.
91. Grimes DA. Primary prevention of ovarian cancer. *JAMA* 1993;270:2855–2856.
92. Egli GE, Newton MD. The transport of carbon particles in the human female reproductive tract. *Fertil Steril* 1961;12:151–155.
93. Villard L, Murphy M. Endometrial cancer trends in England and Wales: a possible protective effect of oral contraception. *Int J Epidemiol* 1990;19:255–258.
94. Villard-Mackintosh L, Vessey MP, Jones L. The effects of oral contraceptives and parity on ovarian cancer trends in women under 55 years of age. *Br J Obstet Gynaecol* 1989;96:783–788.
95. Ries LAG, Miller BA, Hankey RF, et al, eds. *SEER Cancer Statistic Review, 1973–1991: tables and graphs*. Bethesda: National Cancer Institute, 1994.
96. Peipert J, Gutmann J. Oral contraceptive risk assessment: a survey of 247 educated women. *Obstet Gynecol* 1993;82:112–117.
97. Cohen DA, Dent C, MacKinnon D, Hahn G. Condoms for men, not women. *Sex Transm Dis* 1992;19:245–251.
98. Peterson LS. *Contraceptive use in the United States, 1982–90. Advance data from vital and health statistics; no. 260*. Hyattsville, MD: National Center for Health Statistics, 1995.
99. Hill AB. *Principles of medical statistics*. 9th ed. London: Lancet, 1971:313.
100. Greenwald P, Kelloff G, Burch-Whitman C, et al. Chemoprevention. *CA Cancer J Clin* 1995;45:31–49.
101. Vessey MP. The Jephcott Lecture, 1989. An overview of the benefits and risks of combined oral contraceptives. In: Mann RD, ed. *Oral contraceptives and breast cancer*. Carnforth, England: Parthenon Publishing Group, 1990:121–135.
102. Hatcher RA, Guest F, Stewart F, et al. *Contraceptive technology*. 16th rev ed. New York: Irvington, 1994.
103. Schlesselman JJ. Net effect of oral contraceptive use on the risk of cancer in women in the United States. *Obstet Gynecol* 1995;85:793–801.